Single and multiple dose pharmacokinetics of gentamicin administered intravenously and intramuscularly in adult conditioned thoroughbred mares. 1995

G E Swan, and A J Guthrie, and M S Mülders, and V M Killeen, and J P Nurton, and C R Short, and J S van den Berg
Department of Pharmacology and Toxicology, Faculty of Veterinary Science, University of Pretoria, Onderstepoort, Republic of South Africa.

The pharmacokinetics of gentamicin following single and multiple intravenous and intramuscular doses were compared in a two phase, randomised cross-over study in horses. Gentamicin was administered to 6 healthy, conditioned Thoroughbred mares at a dosage of 3.3 mg/kg body weight every 12 hours for 5 intravenous or intramuscular consecutive treatments. Equal numbers of horses were treated by either route during each phase. There was a wash-out period of 5 days between phases. During each phase serial blood samples were collected from each mare immediately before treatment and at 16 intervals following the first and fifth administrations. Blood samples were also collected immediately before treatment and at 30 and 60 minutes following doses 2 through to 4. Gentamicin plasma concentrations were determined by fluorescence polarisation immunoassay. Plasma gentamicin concentration versus time data for both single and multiple doses by either route was best described by a 2 compartmental open model with first order rate constants. A distribution half-life (T1/2 alpha) of 0.1 +/- 0.1 hours, terminal half-life (T1/2 beta) of 1.2 +/- 0.2 hours, mean residence time (MRT) of 1.4 +/- 0.1 hours and total body clearance (ClB) of 1.4 +/- 0.2 ml/kg/min were observed following multidose gentamicin intravenous administration. The volume of distribution at steady state (Vdss) was 117.6 +/- 10.8 ml/kg. No significant differences (P > 0.05) were observed for any of the parameters between single or multiple doses for either route of administration. Except for AUC, significant (P < or = 0.05) differences were observed between multiple intravenous and intramuscular treatments for all pharmacokinetic parameters determined.(ABSTRACT TRUNCATED AT 250 WORDS)

UI MeSH Term Description Entries
D007273 Injections, Intramuscular Forceful administration into a muscle of liquid medication, nutrient, or other fluid through a hollow needle piercing the muscle and any tissue covering it. Intramuscular Injections,Injection, Intramuscular,Intramuscular Injection
D007275 Injections, Intravenous Injections made into a vein for therapeutic or experimental purposes. Intravenous Injections,Injection, Intravenous,Intravenous Injection
D005260 Female Females
D005839 Gentamicins A complex of closely related aminoglycosides obtained from MICROMONOSPORA purpurea and related species. They are broad-spectrum antibiotics, but may cause ear and kidney damage. They act to inhibit PROTEIN BIOSYNTHESIS. Gentamicin Sulfate (USP),Gentamycin,G-Myticin,Garamycin,Gentacycol,Gentamicin,Gentamicin Sulfate,Gentamycins,Gentavet,Genticin,G Myticin,GMyticin,Sulfate, Gentamicin
D006736 Horses Large, hoofed mammals of the family EQUIDAE. Horses are active day and night with most of the day spent seeking and consuming food. Feeding peaks occur in the early morning and late afternoon, and there are several daily periods of rest. Equus caballus,Equus przewalskii,Horse, Domestic,Domestic Horse,Domestic Horses,Horse,Horses, Domestic
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000900 Anti-Bacterial Agents Substances that inhibit the growth or reproduction of BACTERIA. Anti-Bacterial Agent,Anti-Bacterial Compound,Anti-Mycobacterial Agent,Antibacterial Agent,Antibiotics,Antimycobacterial Agent,Bacteriocidal Agent,Bacteriocide,Anti-Bacterial Compounds,Anti-Mycobacterial Agents,Antibacterial Agents,Antibiotic,Antimycobacterial Agents,Bacteriocidal Agents,Bacteriocides,Agent, Anti-Bacterial,Agent, Anti-Mycobacterial,Agent, Antibacterial,Agent, Antimycobacterial,Agent, Bacteriocidal,Agents, Anti-Bacterial,Agents, Anti-Mycobacterial,Agents, Antibacterial,Agents, Antimycobacterial,Agents, Bacteriocidal,Anti Bacterial Agent,Anti Bacterial Agents,Anti Bacterial Compound,Anti Bacterial Compounds,Anti Mycobacterial Agent,Anti Mycobacterial Agents,Compound, Anti-Bacterial,Compounds, Anti-Bacterial
D016231 Fluorescence Polarization Immunoassay Fluoroimmunoassay where detection of the hapten-antibody reaction is based on measurement of the increased polarization of fluorescence-labeled hapten when it is combined with antibody. The assay is very useful for the measurement of small haptenic antigens such as drugs at low concentrations. Immunoassay, Fluorescence Polarization,Polarization Fluoroimmunoassay,Fluorescence Polarization Immunoassays,Fluoroimmunoassay, Polarization,Fluoroimmunoassays, Polarization,Immunoassays, Fluorescence Polarization,Polarization Fluoroimmunoassays,Polarization Immunoassay, Fluorescence,Polarization Immunoassays, Fluorescence
D018592 Cross-Over Studies Studies comparing two or more treatments or interventions in which the subjects or patients, upon completion of the course of one treatment, are switched to another. In the case of two treatments, A and B, half the subjects are randomly allocated to receive these in the order A, B and half to receive them in the order B, A. A criticism of this design is that effects of the first treatment may carry over into the period when the second is given. (Last, A Dictionary of Epidemiology, 2d ed) Cross-Over Design,Cross-Over Trials,Crossover Design,Crossover Studies,Crossover Trials,Cross Over Design,Cross Over Studies,Cross Over Trials,Cross-Over Designs,Cross-Over Study,Crossover Designs,Crossover Study,Design, Cross-Over,Design, Crossover,Designs, Cross-Over,Designs, Crossover,Studies, Cross-Over,Studies, Crossover,Study, Cross-Over,Study, Crossover,Trial, Cross-Over,Trial, Crossover,Trials, Cross-Over,Trials, Crossover

Related Publications

G E Swan, and A J Guthrie, and M S Mülders, and V M Killeen, and J P Nurton, and C R Short, and J S van den Berg
October 1998, Journal of the American Veterinary Medical Association,
G E Swan, and A J Guthrie, and M S Mülders, and V M Killeen, and J P Nurton, and C R Short, and J S van den Berg
June 1989, Journal of veterinary pharmacology and therapeutics,
G E Swan, and A J Guthrie, and M S Mülders, and V M Killeen, and J P Nurton, and C R Short, and J S van den Berg
September 1988, American journal of veterinary research,
G E Swan, and A J Guthrie, and M S Mülders, and V M Killeen, and J P Nurton, and C R Short, and J S van den Berg
February 1996, Journal of veterinary pharmacology and therapeutics,
G E Swan, and A J Guthrie, and M S Mülders, and V M Killeen, and J P Nurton, and C R Short, and J S van den Berg
October 1984, Antimicrobial agents and chemotherapy,
G E Swan, and A J Guthrie, and M S Mülders, and V M Killeen, and J P Nurton, and C R Short, and J S van den Berg
October 1985, Antimicrobial agents and chemotherapy,
G E Swan, and A J Guthrie, and M S Mülders, and V M Killeen, and J P Nurton, and C R Short, and J S van den Berg
August 1997, Antimicrobial agents and chemotherapy,
G E Swan, and A J Guthrie, and M S Mülders, and V M Killeen, and J P Nurton, and C R Short, and J S van den Berg
December 1990, Journal of veterinary pharmacology and therapeutics,
G E Swan, and A J Guthrie, and M S Mülders, and V M Killeen, and J P Nurton, and C R Short, and J S van den Berg
April 1988, American journal of veterinary research,
G E Swan, and A J Guthrie, and M S Mülders, and V M Killeen, and J P Nurton, and C R Short, and J S van den Berg
April 1992, The Journal of antimicrobial chemotherapy,
Copied contents to your clipboard!